↓ Skip to main content

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, May 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

news
2 news outlets
twitter
4 X users

Citations

dimensions_citation
42 Dimensions

Readers on

mendeley
79 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease
Published in
Alzheimer's Research & Therapy, May 2021
DOI 10.1186/s13195-021-00843-2
Pubmed ID
Authors

Niels D. Prins, John E. Harrison, Hui-May Chu, Kelly Blackburn, John J. Alam, Philip Scheltens

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 79 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 11%
Student > Ph. D. Student 7 9%
Student > Bachelor 6 8%
Student > Master 6 8%
Other 3 4%
Other 10 13%
Unknown 38 48%
Readers by discipline Count As %
Medicine and Dentistry 11 14%
Neuroscience 7 9%
Nursing and Health Professions 4 5%
Biochemistry, Genetics and Molecular Biology 3 4%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Other 9 11%
Unknown 42 53%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 July 2023.
All research outputs
#1,882,814
of 24,696,958 outputs
Outputs from Alzheimer's Research & Therapy
#342
of 1,384 outputs
Outputs of similar age
#47,269
of 439,221 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#15
of 49 outputs
Altmetric has tracked 24,696,958 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,384 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.6. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,221 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.